SWTX Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -63.08%. SpringWorks Therapeutics's return on equity of -46.69% beat Axsome Therapeutics's return on equity of -244.32%.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 99.82%. On the other hand Axsome Therapeutics has an analysts' consensus of $173.89 which suggests that it could grow by 77.33%. Given that SpringWorks Therapeutics has higher upside potential than Axsome Therapeutics, analysts believe SpringWorks Therapeutics is more attractive than Axsome Therapeutics.

SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.73%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. SpringWorks Therapeutics's net income of -$77.3M is lower than Axsome Therapeutics's net income of -$74.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 14.11x versus 12.18x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Baxter International has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -18.6%. SpringWorks Therapeutics's return on equity of -46.69% beat Baxter International's return on equity of -8.24%.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 99.82%. On the other hand Baxter International has an analysts' consensus of $39.74 which suggests that it could grow by 42.75%. Given that SpringWorks Therapeutics has higher upside potential than Baxter International, analysts believe SpringWorks Therapeutics is more attractive than Baxter International.

SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Baxter International has a beta of 0.645, suggesting its less volatile than the S&P 500 by 35.462%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Baxter International offers a yield of 3.31% to investors and pays a quarterly dividend of $0.17 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Baxter International quarterly revenues of $2.8B. SpringWorks Therapeutics's net income of -$77.3M is higher than Baxter International's net income of -$512M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 14.11x versus 1.11x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

Grace Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -46.69% beat Grace Therapeutics's return on equity of --.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 99.82%. On the other hand Grace Therapeutics has an analysts' consensus of $11.86 which suggests that it could grow by 499.01%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.

SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Grace Therapeutics has a beta of 1.327, suggesting its more volatile than the S&P 500 by 32.655%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grace Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Grace Therapeutics pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Grace Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$77.3M is lower than Grace Therapeutics's net income of -$4.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Grace Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 14.11x versus -- for Grace Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Insmed has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -225.53%. SpringWorks Therapeutics's return on equity of -46.69% beat Insmed's return on equity of -41989.34%.

SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 99.82%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 39.68%. Given that SpringWorks Therapeutics has higher upside potential than Insmed, analysts believe SpringWorks Therapeutics is more attractive than Insmed.

SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.

SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.

SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Insmed quarterly revenues of $104.4M. SpringWorks Therapeutics's net income of -$77.3M is higher than Insmed's net income of -$235.5M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 14.11x versus 30.92x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.